> 资讯
Stratipath and Roche Join Forces to Help Expand Access to AI-Powered Precision Diagnostics
GlobeNewswire 2024-09-09 21:55:29 资讯
Stratipath, a global leader in artificial intelligence (AI)-based precision diagnostic solutions, is thrilled to announce a collaboration with Roche, the world’s largest biotechnology company and the global leader in in-vitro diagnostics. In this non-exclusive collaboration, Roche will have the distribution rights to the integrated Stratipath solution, Stratipath Breast. The integration between Stratipath Breast and Roche’s navify® Digital Pathology enterprise software enables Roche customers to seamlessly perform prognostic risk profiling analyses directly from navify® Digital Pathology platform.
Stockholm - Sweden, Sept. 09, 2024 (GLOBE NEWSWIRE) --
| Stratipath, a global leader in artificial intelligence (AI)-based precision diagnostic solutions, is thrilled to announce a collaboration with Roche, the world’s largest biotechnology company and the global leader in in-vitro diagnostics. In this non-exclusive collaboration, Roche will have the distribution rights to the integrated Stratipath solution, Stratipath Breast. The integration between Stratipath Breast and Roche’s navify® Digital Pathology enterprise software enables Roche customers to seamlessly perform prognostic risk profiling analyses directly from navify® Digital Pathology platform. Stratipath Breast is the first EU regulatory-compliant solution for risk stratification of breast cancer using AI-based precision diagnostics. This deep learning-based solution analyses digitised haematoxylin and eosin-stained histopathology images of breast cancer tissue to enable the identification of patients with increased risk of disease progression, thus providing novel decision support for clinicians in the diagnostic evaluation of breast cancer. In contrast to conventional molecular tests, AI-based risk profiling offers shorter turnaround times for results, delivers new insights at the point of diagnosis, and substantially reduces the reliance on expensive molecular testing. As a result, Stratipath Breast provides broader accessibility and benefits for a greater number of breast cancer patients. "Stratipath Breast represents a significant advancement by offering a faster and more cost-effective alternative to traditional molecular assays. By integrating with Roche’s navify® Digital Pathology enterprise software, a large number of pathology labs globally now gain rapid access to AI-based prognostic insights, all while streamlining laboratory processes and minimising costs." says Fredrik Wetterhall, CEO and co-founder of Stratipath. This collaboration between Stratipath and Roche represents a significant step forward in breast cancer diagnostics. By harnessing the power of artificial intelligence and digital pathology, the two organisations are committed to improving the lives of breast cancer patients worldwide. |
||
|
Lars Lengquist Stratipath +46 709574782 lars.lengquist.press@stratipath.com |
相关推荐
- Stratipath and Roche Join Forces to Help Expand Access to AI-Powered Precision Diagnostics
- VistaJet Connects China-Africa Business Ties, Propelling Cross-Continental Commerce
- 维思达公务机联系中国和非洲商务，推动中非商业发展
- 定义AI Agent四大核心能力，荣耀IFA剧透端侧AI创新进展
- Meta做不到的，这家创业公司做到了
- 凤凰湾区财经论坛揭秘：赛轮集团袁仲雪畅谈中国“智造”扬帆海外
- 千寻位置CEO陈金培：构建北斗时空智能新质生产力“朋友圈”
- 众安集团：精耕稳进 扎牢底盘 谋持久发展
- 赛轮集团加速冲刺：民族品牌崛起，挺进全球轮胎前十强
- 《凡人歌》高燃热播 王骁逆境中磨砺成长 谱写凡人的“非凡”乐章
- 搜索
-
- 09-09Stratipath and Roche Join Forces to Help Expand Access to AI-Powered Precision Diagnostics
- 09-09VistaJet Connects China-Africa Business Ties, Propelling Cross-Continental Commerce
- 09-09维思达公务机联系中国和非洲商务，推动中非商业发展
- 09-09定义AI Agent四大核心能力，荣耀IFA剧透端侧AI创新进展
- 09-09Meta做不到的，这家创业公司做到了
- 09-09凤凰湾区财经论坛揭秘：赛轮集团袁仲雪畅谈中国“智造”扬帆海外
- 09-09千寻位置CEO陈金培：构建北斗时空智能新质生产力“朋友圈”
- 09-09众安集团：精耕稳进 扎牢底盘 谋持久发展
- 09-09赛轮集团加速冲刺：民族品牌崛起，挺进全球轮胎前十强
- 09-09《凡人歌》高燃热播 王骁逆境中磨砺成长 谱写凡人的“非凡”乐章
- 标签列表